Company Insights

PYPD supplier relationships

Explore interactive graphBrowse insights index
PYPD supplier relationship map

PolyPid (PYPD) supplier landscape: investor briefing and relationship inventory

PolyPid Ltd. develops and commercializes drug-delivery products built on its Polymer Lipid Encapsulation Matrix (PLEX) platform, monetizing through proprietary product development, regulatory approvals, and selective commercial or licensing partnerships that convert clinical programs into revenue-bearing products. The company is pre-revenue, relies on regulatory milestones for value realization, and uses outsourced investor relations and regional commercial partners to manage market access and communications. For an at-a-glance supplier and partner read, visit https://nullexposure.com/.

Operationally, PolyPid generates value by advancing clinical-stage assets (notably D-PLEX), converting positive regulatory interactions into NDA filings, and transferring commercialization risk to partners where scale or regional expertise is required. Key commercial levers are regulatory success, successful partner licensing, and disciplined capital management.

How PolyPid’s business model drives supplier and partner needs

PolyPid is an advanced-stage biotech with no product revenue reported in recent filings (Revenue TTM = 0). That creates a predictable supplier posture: the company contracts for specialist services—regulatory consultants, IR firms, and regional distributors—rather than large-scale manufacturing or sales networks today. Concentration is high (a small number of named partners and outsourcers handle critical functions), criticality is concentrated on regulatory and investor communications, and maturity is typical for a clinical-stage biotech: value is event-driven (FDA meetings, clinical readouts, licensing deals). Institutional ownership (~32%) and insider ownership (~21%) indicate engaged stakeholders that monitor milestone progress closely.

For deeper vendor mapping and exposure scoring, see https://nullexposure.com/.

Reported relationships (full inventory)

Below is a complete, itemized review of every relationship record surfaced in the supplier search results. Each entry is a plain-English description with the origin of the disclosure.

  1. Arx Investor Relations — Sahm Capital announcement (2025-12-16)
    PolyPid lists ARX Investor Relations as its North American investor relations contact; ARX handles press and investor outreach. Source: SahmCapital news release dated 2025-12-16 (polypid@arxhq.com) — https://www.sahmcapital.com/news/content/polypid-appoints-veteran-medtech-leader-brooke-story-as-chairman-of-the-board-of-directors-2025-12-16.

  2. Arx Investor Relations — GlobeNewswire release (2025-12-03)
    The company again identifies ARX Investor Relations as the contact in the GlobeNewswire release announcing positive FDA pre‑NDA meeting minutes for D-PLEX. Source: GlobeNewswire, 2025-12-03 — https://www.globenewswire.com/news-release/2025/12/03/3198886/0/en/PolyPid-Announces-Positive-FDA-Pre-NDA-Meeting-Minutes-for-D-PLEX-Supporting-NDA-Submission.html.

  3. Arx Investor Relations — Yahoo Finance report (2025-12-03)
    A Yahoo Finance post syndicates the positive FDA pre‑NDA announcement and lists ARX as the investor relations desk. Source: Yahoo Finance coverage, 2025-12-03 — https://finance.yahoo.com/news/polypid-announces-positive-fda-pre-133000084.html.

  4. Arx Investor Relations — GlobeNewswire Q3 report (2025-10-29)
    In the Q3 financial results release, PolyPid provides ARX Investor Relations contact information for North American inquiries. Source: GlobeNewswire press release, 2025-10-29 — https://www.globenewswire.com/news-release/2025/10/29/3176430/0/en/PolyPid-to-Report-Third-Quarter-2025-Financial-Results-and-Operational-Highlights-on-November-12-2025.html.

  5. Arx Investor Relations — GlobeNewswire (duplicate of FDA pre‑NDA release) (2025-12-03)
    The dataset contains a second GlobeNewswire entry reiterating ARX as the IR desk in the FDA pre‑NDA announcement. Source: GlobeNewswire, 2025-12-03 — https://www.globenewswire.com/news-release/2025/12/03/3198886/0/en/PolyPid-Announces-Positive-FDA-Pre-NDA-Meeting-Minutes-for-D-PLEX-Supporting-NDA-Submission.html.

  6. Arx Investor Relations — GlobeNewswire Q4 report notice (2026-01-28)
    PolyPid uses ARX to announce the Q4 2025 results date; ARX is the primary conduit for calendar and earnings logistics in North America. Source: GlobeNewswire, 2026-01-28 — https://www.globenewswire.com/news-release/2026/01/28/3227536/0/en/polypid-to-report-fourth-quarter-2025-financial-results-and-operational-highlights-on-february-11-2026.html.

  7. Arx Investor Relations — GlobeNewswire duplicate (2026-01-28)
    A second GlobeNewswire entry repeats the Q4 reporting announcement with the same ARX contact information. Source: GlobeNewswire, 2026-01-28 — https://www.globenewswire.com/news-release/2026/01/28/3227536/0/en/PolyPid-to-Report-Fourth-Quarter-2025-Financial-Results-and-Operational-Highlights-on-February-11-2026.html.

  8. Arx Investor Relations — GlobeNewswire investor conference participation (2026-02-25)
    PolyPid announces participation in upcoming investor conferences and again lists ARX Investor Relations as the North American desk. Source: GlobeNewswire, 2026-02-25 — https://www.globenewswire.com/news-release/2026/02/25/3244614/0/en/polypid-announces-participation-in-upcoming-investor-conferences.html.

  9. Arx Investor Relations — GlobeNewswire duplicate (2026-02-25)
    A duplicate GlobeNewswire entry referenced investor conference participation and ARX contact information. Source: GlobeNewswire, 2026-02-25 — https://www.globenewswire.com/news-release/2026/02/25/3244614/0/en/PolyPid-Announces-Participation-in-Upcoming-Investor-Conferences.html.

  10. Advance Pharma — InsiderMonkey Q3 2025 earnings call transcript (FY2025)
    Management states that Advance Pharma is PolyPid’s exclusive partner for Europe, establishing a clear regional commercialization conduit outside North America. Source: Q3 2025 earnings call transcript reported on InsiderMonkey — https://www.insidermonkey.com/blog/polypid-ltd-nasdaqpypd-q3-2025-earnings-call-transcript-1644717/.

  11. ARX Investor Relations — InsiderMonkey Q3 2025 transcript (FY2025)
    The Q3 2025 call transcript records Yehuda Leibler from ARX hosting the call, confirming ARX’s active role in investor communications and earnings event management. Source: InsiderMonkey transcript, Q3 2025 — https://www.insidermonkey.com/blog/polypid-ltd-nasdaqpypd-q3-2025-earnings-call-transcript-1644717/.

  12. Arx Investor Relations — Yahoo Finance investor conference announcement (2025)
    Yahoo Finance syndication of a conference participation notice lists ARX again as the investor relations contact. Source: Yahoo Finance report, 2025 — https://finance.yahoo.com/news/polypid-participate-roth-capital-partners-133000633.html.

  13. Arx Investor Relations — GlobeNewswire corporate update (2025-11-12)
    In the Q3 financials and corporate update release, ARX is the listed North American IR desk for investor questions. Source: GlobeNewswire release, 2025-11-12 — https://www.globenewswire.com/news-release/2025/11/12/3186113/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Third-Quarter-2025-Financial-Results.html.

What these relationships imply for supplier risk and contracting posture

  • Investor relations consolidation: Multiple entries show ARX Investor Relations as the single named North American IR contact across press releases and earnings calls. This indicates a centralized communications supplier posture and the outsourcing of investor engagement to a single specialist firm, increasing vendor criticality for market messaging and event management.
  • Geographic commercial segmentation: The explicit naming of Advance Pharma as the exclusive European partner signals a regional distribution strategy: PolyPid retains development and regulatory work while delegating European commercialization to a single partner, concentrating commercial execution risk in that relationship.
  • Event-driven dependency: Frequent references to FDA pre‑NDA minutes and scheduled earnings or conference participation underscore that value realization is milestone-driven, making regulatory consultants and investor relations crucial operational suppliers even before product revenues begin.
  • Maturity and financial constraints: Company-level financials show pre-revenue status (Revenue TTM = 0), negative EBITDA, and negative EPS, producing a contracting posture that favors fixed-term specialist contracts and partnerships over broad in‑house commercialization investment.

Investment implications and risk posture

  • Catalyst-centric upside: Regulatory milestones (FDA pre‑NDA feedback) and partner-led commercialization in Europe are the primary near-term value drivers for investors. Positive regulatory feedback reported in December 2025 is a tangible milestone that de-risks the NDA path for D-PLEX.
  • Concentration risk: A small set of named external partners—ARX for investor relations and Advance Pharma for Europe—creates single-point-of-failure exposures in communications and regional market access; contract terms, exclusivity clauses, and termination protections are material to valuation.
  • Balance sheet pressure: With no product revenue and negative operating metrics, PolyPid’s ability to execute on clinical and regulatory timelines depends on capital markets access and partner-funded activities; institutional ownership and active IR support are therefore strategic operating levers.

For supplier exposure mapping and transactional risk scoring, consult https://nullexposure.com/.

Practical next steps for investors and operators

  • Review the Advance Pharma commercial agreement (territory, exclusivity, milestones, and termination provisions) to quantify European launch risk and revenue timing.
  • Confirm ARX Investor Relations’ engagement terms and disclosure control processes to assess market communications reliability around upcoming regulatory milestones.
  • Monitor regulatory filings and upcoming earnings dates listed in GlobeNewswire/Yahoo syndications for event-driven price sensitivity.

If you want a summarized supplier exposure report or a tailored partner-risk checklist on PolyPid, start here: https://nullexposure.com/.

Closing note: PolyPid’s short-term valuation is tethered to regulatory and partner execution rather than current sales, and its supplier footprint—compact but critical—reflects a strategic decision to outsource investor communications and regional commercialization while preserving capital for clinical and regulatory work. For customized intelligence and supplier risk profiling, visit https://nullexposure.com/.